SI2731972T1 - Anti-folate receptor alpha antibodies and uses thereof - Google Patents
Anti-folate receptor alpha antibodies and uses thereof Download PDFInfo
- Publication number
- SI2731972T1 SI2731972T1 SI201231234T SI201231234T SI2731972T1 SI 2731972 T1 SI2731972 T1 SI 2731972T1 SI 201231234 T SI201231234 T SI 201231234T SI 201231234 T SI201231234 T SI 201231234T SI 2731972 T1 SI2731972 T1 SI 2731972T1
- Authority
- SI
- Slovenia
- Prior art keywords
- seq
- amino acid
- acid sequence
- fra
- antibody
- Prior art date
Links
- 102000006815 folate receptor Human genes 0.000 title claims 14
- 108020005243 folate receptor Proteins 0.000 title claims 14
- 102000010451 Folate receptor alpha Human genes 0.000 claims abstract 56
- 108050001931 Folate receptor alpha Proteins 0.000 claims abstract 56
- 238000000034 method Methods 0.000 claims abstract 26
- 239000000427 antigen Substances 0.000 claims abstract 25
- 102000036639 antigens Human genes 0.000 claims abstract 25
- 108091007433 antigens Proteins 0.000 claims abstract 25
- 239000012634 fragment Substances 0.000 claims abstract 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract 18
- 239000000523 sample Substances 0.000 claims abstract 7
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 5
- 102000040430 polynucleotide Human genes 0.000 claims abstract 5
- 108091033319 polynucleotide Proteins 0.000 claims abstract 5
- 239000002157 polynucleotide Substances 0.000 claims abstract 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 4
- 201000005202 lung cancer Diseases 0.000 claims abstract 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 4
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 206010009944 Colon cancer Diseases 0.000 claims abstract 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract 3
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract 3
- 201000002510 thyroid cancer Diseases 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 49
- 201000011510 cancer Diseases 0.000 claims 15
- 210000004027 cell Anatomy 0.000 claims 14
- 239000012472 biological sample Substances 0.000 claims 11
- 229940014144 folate Drugs 0.000 claims 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 11
- 235000019152 folic acid Nutrition 0.000 claims 11
- 239000011724 folic acid Substances 0.000 claims 11
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 208000009956 adenocarcinoma Diseases 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 230000002349 favourable effect Effects 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241000009328 Perro Species 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000003040 circulating cell Anatomy 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000001114 immunoprecipitation Methods 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 abstract 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 abstract 1
- 239000013068 control sample Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000013074 reference sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508444P | 2011-07-15 | 2011-07-15 | |
| US201261604412P | 2012-02-28 | 2012-02-28 | |
| US201261604954P | 2012-02-29 | 2012-02-29 | |
| EP12736054.3A EP2731972B1 (en) | 2011-07-15 | 2012-07-13 | Anti-folate receptor alpha antibodies and uses thereof |
| PCT/US2012/046672 WO2013012722A1 (en) | 2011-07-15 | 2012-07-13 | Anti-folate receptor alpha antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2731972T1 true SI2731972T1 (en) | 2018-04-30 |
Family
ID=46516898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231234T SI2731972T1 (en) | 2011-07-15 | 2012-07-13 | Anti-folate receptor alpha antibodies and uses thereof |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8475795B2 (enExample) |
| EP (2) | EP3330291B1 (enExample) |
| JP (2) | JP6220333B2 (enExample) |
| CN (2) | CN107011439B (enExample) |
| AU (3) | AU2012284321C1 (enExample) |
| BR (1) | BR112014001030A2 (enExample) |
| CA (1) | CA2841725C (enExample) |
| CY (1) | CY1120600T1 (enExample) |
| DK (1) | DK2731972T3 (enExample) |
| ES (2) | ES2824498T3 (enExample) |
| HR (1) | HRP20180353T1 (enExample) |
| HU (1) | HUE036929T2 (enExample) |
| LT (1) | LT2731972T (enExample) |
| PL (1) | PL2731972T3 (enExample) |
| PT (1) | PT2731972T (enExample) |
| RS (1) | RS56985B1 (enExample) |
| SG (1) | SG10201605278PA (enExample) |
| SI (1) | SI2731972T1 (enExample) |
| SM (1) | SMT201800150T1 (enExample) |
| TR (1) | TR201802838T4 (enExample) |
| WO (1) | WO2013012722A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5778700B2 (ja) | 2010-02-24 | 2015-09-16 | イミュノジェン， インコーポレイテッド | フォレート受容体１抗体及びそのイムノコンジュゲート及び使用 |
| ES2661466T3 (es) | 2011-04-01 | 2018-04-02 | Immunogen, Inc. | Métodos para aumentar la eficacia de la terapia contra el cáncer con FOLR1 |
| EP3330291B1 (en) * | 2011-07-15 | 2020-09-02 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| DK2890717T3 (da) * | 2012-08-31 | 2020-05-11 | Immunogen Inc | Diagnostiske assays og kits til detektering af folatreceptor 1 |
| WO2014205342A2 (en) | 2013-06-20 | 2014-12-24 | Morphotek, Inc. | Methods for treatment of ovarian cancer |
| CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| AU2015255883A1 (en) * | 2014-05-08 | 2016-10-27 | Novodiax, Inc. | Direct immunohistochemistry assay |
| CA2966566C (en) | 2014-11-20 | 2024-03-19 | F. Hoffmann-La Roche Ag | Combination therapy of t cell activating bispecific antigen binding molecules cd3 and folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| MA40972B1 (fr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 |
| MX2017013390A (es) | 2015-04-17 | 2018-06-13 | Morphotek Inc | Método para el tratamiento de cáncer pulmonar. |
| CN108601828B (zh) | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| WO2018031968A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| MX2019001755A (es) | 2016-08-12 | 2019-05-09 | L E A F Holdings Group Llc | Antifolatos poliglutamados y sus usos. |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN107446021B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽5及其应用 |
| CN107793471B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽4及其应用 |
| CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
| CN107446020B (zh) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | 叶酸受体α特异性结合肽2及其应用 |
| JP7604226B2 (ja) * | 2017-09-05 | 2024-12-23 | イミュノジェン， インコーポレイテッド | 患者の試料中のヒト葉酸受容体１を検出するための方法 |
| US12246015B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| CN111954529A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化氨甲蝶呤及其用途 |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| CA3090500A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| US12246019B2 (en) | 2018-02-07 | 2025-03-11 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
| CN111954530A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
| US12310966B2 (en) | 2018-02-07 | 2025-05-27 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| WO2019157138A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
| JP7514533B2 (ja) | 2018-02-07 | 2024-07-11 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化テトラヒドロ葉酸およびその使用 |
| EP3755335A4 (en) | 2018-02-14 | 2022-06-22 | L.E.A.F Holdings Group LLC | GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES |
| WO2019160736A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| WO2019160733A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12350271B2 (en) | 2018-02-14 | 2025-07-08 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US11873335B2 (en) | 2018-03-13 | 2024-01-16 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| TWI865456B (zh) | 2018-07-09 | 2024-12-11 | 大陸商沐特圖公司 | 葉酸受體阿法特異性抗體 |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| WO2021247821A1 (en) * | 2020-06-03 | 2021-12-09 | The Wistar Institute Of Anatomy And Biology | Monoclonal antibodies against human siglec-9 and use thereof for immunotherapy |
| CN117730098A (zh) * | 2021-06-04 | 2024-03-19 | 伊缪诺金公司 | 治疗具有可溶性FR-α的患者的癌症 |
| WO2023009529A2 (en) | 2021-07-28 | 2023-02-02 | Trustees Of Boston University | Novel polypeptides and uses thereof |
| WO2024104431A1 (zh) * | 2022-11-16 | 2024-05-23 | 迈威(上海)生物科技股份有限公司 | 一种靶向FRα的抗体或其抗原结合片段及其应用 |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
| CN120554514B (zh) * | 2025-07-29 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体 |
| CN120842412B (zh) * | 2025-09-23 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| WO2004082463A2 (en) | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
| JP2007537709A (ja) | 2003-05-23 | 2007-12-27 | モーフオテク・インコーポレーテツド | 腫瘍抗原を特異的に結合するモノクローナル抗体 |
| EP1716179A2 (en) | 2004-02-12 | 2006-11-02 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| EP1864133B1 (en) | 2005-03-30 | 2010-03-10 | Purdue Research Foundation | Method for breastcancer prognosis using cellular folate vitamin receptor quantification |
| WO2006116592A2 (en) * | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
| FR2918994B1 (fr) | 2007-07-20 | 2012-10-19 | Rhodia Operations | Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux. |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| CA2816991C (en) * | 2010-11-05 | 2020-06-09 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| WO2012119077A1 (en) | 2011-03-02 | 2012-09-07 | Morphotek Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| EP3330291B1 (en) * | 2011-07-15 | 2020-09-02 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
-
2012
- 2012-07-13 EP EP17196948.8A patent/EP3330291B1/en active Active
- 2012-07-13 SM SM20180150T patent/SMT201800150T1/it unknown
- 2012-07-13 PT PT127360543T patent/PT2731972T/pt unknown
- 2012-07-13 DK DK12736054.3T patent/DK2731972T3/en active
- 2012-07-13 SI SI201231234T patent/SI2731972T1/en unknown
- 2012-07-13 US US13/548,775 patent/US8475795B2/en active Active
- 2012-07-13 WO PCT/US2012/046672 patent/WO2013012722A1/en not_active Ceased
- 2012-07-13 JP JP2014520368A patent/JP6220333B2/ja active Active
- 2012-07-13 ES ES17196948T patent/ES2824498T3/es active Active
- 2012-07-13 RS RS20180252A patent/RS56985B1/sr unknown
- 2012-07-13 EP EP12736054.3A patent/EP2731972B1/en active Active
- 2012-07-13 SG SG10201605278PA patent/SG10201605278PA/en unknown
- 2012-07-13 PL PL12736054T patent/PL2731972T3/pl unknown
- 2012-07-13 TR TR2018/02838T patent/TR201802838T4/tr unknown
- 2012-07-13 BR BR112014001030A patent/BR112014001030A2/pt not_active Application Discontinuation
- 2012-07-13 HR HRP20180353TT patent/HRP20180353T1/hr unknown
- 2012-07-13 HU HUE12736054A patent/HUE036929T2/hu unknown
- 2012-07-13 AU AU2012284321A patent/AU2012284321C1/en active Active
- 2012-07-13 CN CN201611025725.1A patent/CN107011439B/zh active Active
- 2012-07-13 ES ES12736054.3T patent/ES2663556T3/es active Active
- 2012-07-13 LT LTEP12736054.3T patent/LT2731972T/lt unknown
- 2012-07-13 CA CA2841725A patent/CA2841725C/en active Active
- 2012-07-13 CN CN201280043606.2A patent/CN103998467B/zh active Active
-
2013
- 2013-03-13 US US13/800,575 patent/US8834877B2/en active Active
-
2014
- 2014-08-04 US US14/451,044 patent/US9599621B2/en active Active
-
2017
- 2017-02-16 US US15/434,326 patent/US10101343B2/en active Active
- 2017-04-11 AU AU2017202365A patent/AU2017202365B2/en active Active
- 2017-09-29 JP JP2017190224A patent/JP6526143B2/ja active Active
-
2018
- 2018-03-01 CY CY181100260T patent/CY1120600T1/el unknown
- 2018-09-26 AU AU2018236755A patent/AU2018236755B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2731972T1 (en) | Anti-folate receptor alpha antibodies and uses thereof | |
| JP2014524744A5 (enExample) | ||
| JP5689133B2 (ja) | 結腸直腸癌におけるｐｏｄｘｌタンパク質 | |
| US20110091384A1 (en) | Biomarker for identification of melanoma tumor cells | |
| US20100143927A1 (en) | Methods and Assays for Measuring p95 and/or p95 in a Sample and Antibodies Specific for p95 | |
| JP2009540803A5 (enExample) | ||
| JP6445467B2 (ja) | 抗ｐ４０抗体システムおよび方法 | |
| JP2016500659A5 (enExample) | ||
| US20210310080A1 (en) | Composition for diagnosing cancer using potassium channel proteins | |
| JP2016516008A5 (enExample) | ||
| JP2020510409A5 (enExample) | ||
| JP2017505436A5 (enExample) | ||
| CN114787374A (zh) | 基于对治疗的分子反应的治疗方法 | |
| ES2987412T3 (es) | Composiciones y procedimientos para evaluar el riesgo de ocurrencia de cáncer | |
| WO2016172160A1 (en) | Compositions and methods for prostate cancer analysis | |
| JP2015514707A5 (enExample) | ||
| US20130102486A1 (en) | Perp as a prognostic and diagnostic marker for dysplasia and cancer | |
| CA2813098A1 (en) | Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e | |
| CN111133108A (zh) | 抗ckap4单克隆抗体 | |
| WO2014056626A1 (en) | Novel biomarkers for sub-typing pancreatic ductal adenocarcinoma | |
| US12461103B2 (en) | Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto | |
| TW201827465A (zh) | 針對ｆｚｄ１０之單株抗體及其用途 | |
| CN107385091B (zh) | Cdc42bpa作为结直肠癌转移诊断与预测预后的生物标志物 | |
| WO2025026204A1 (en) | Antibodies against ror1 and uses thereof | |
| US20250271434A1 (en) | Method for predicting prognosis of breast cancer patient using ctc expressing c-met |